Medication info

GluLipitin Duo Tablet 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Bright pink, biconvex, oval film-coated tablet
Packaging
60 tablets/box[(10 tablets/PTP*6)]
Approval status
Expired

MFDS item code 202002090 · Approved 2020.03.25

This product's status changed to Expired on 2025.03.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients in whom adequate glycemic control cannot be achieved with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients in whom adequate glycemic control cannot be achieved with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). 5. Patients in whom adequate glycemic control cannot be achieved with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Contraindications).

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. It can be administered when there is no experience with diabetes medication or when blood sugar control is difficult with metformin alone. It can also be used to replace a combination therapy of linagliptin and metformin, or when a combination of maximum dose metformin and sulfonylurea is ineffective. If blood sugar control is still not adequate with insulin and metformin, it can also be administered in combination. Lastly, if blood sugar control is difficult even with a combination of maximum dose metformin and empagliflozin, it may be used in conjunction with empagliflozin. This medication effectively improves blood sugar control through various combination therapies.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients in whom adequate glycemic control cannot be achieved with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients in whom adequate glycemic control cannot be achieved with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). 5. Patients in whom adequate glycemic control cannot be achieved with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Contraindications).

Precautions

This medication is used for diabetes treatment, and one of its main ingredients, metformin, can cause rare but serious side effects such as lactic acidosis, so caution is necessary. This medication includes linagliptin and metformin, and should not be administered to certain patients. For instance, it should not be used in patients with allergies to its components or those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, liver dysfunction, acute alcohol intoxication, pregnant or breastfeeding women. Due to the risk of hypoglycemia, blood glucose levels should be carefully monitored when taken along with insulin or sulfonylurea, and dosage adjustments may be necessary. Metformin is excreted through the kidneys, so it should not be used in patients with renal impairment and renal function should be monitored regularly. Caution should be exercised in patients with poor cardiac function, acute illness, severe infection, dehydration, etc. When undergoing radiological examinations using iodinated contrast agents, this medication should be temporarily discontinued before and after the examination, and re-evaluation of renal function should be conducted before resuming. During use, acute pancreatitis or skin blistering conditions may occur, so if symptoms arise, the physician should be notified immediately. This medication may lower vitamin B12 levels, so it is important to monitor for vitamin B12 deficiency during long-term use. It is recommended not to use this medication in women who are pregnant or planning for pregnancy as well as in children under 10 years of age. Elderly patients may have impaired renal function, so dosage adjustments and regular kidney function tests are necessary. In case of overdose, there is a risk of lactic acidosis. If suspected, immediate hospital treatment is required, and blood dialysis may be beneficial. This medication should be stored out of reach of children, protected from moisture, and not transferred to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • loss of appetite
Show 145 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • constipation
  • upper abdominal pain
  • dyspepsia
  • stomatitis
  • cerebral infarction
  • speech disorder
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • hypotension
  • flushing
  • hepatic steatosis
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • kidney transplant failure
  • anemia
  • dizziness
  • sensory impairment
  • itching
  • hypertension
  • benign prostatic hyperplasia
  • confusion state
  • nocturia
  • dermatitis
  • hyperglycemia
  • loss of appetite
  • insufficient control of diabetes
  • malnutrition
  • hyponatremia
  • dehydration
  • headache
  • sensory abnormality
  • postherpetic neuralgia
  • hemiparesis
  • syncope
  • drowsiness
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • vocal cord polyp
  • dyslipidemia
  • hypercholesterolemia
  • osteoarthritis
  • limb pain
  • myelodysplastic syndrome
  • thyroid nodule
  • vitreous hemorrhage
  • anxiety
  • depression
  • insomnia
  • itching
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • diarrhea
  • pancreatitis
  • stomatitis
  • fever
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • ligament sprain
  • flank pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 degree and 30 degrees Celsius. This way, the medication’s effectiveness can be preserved for a long time.

Appearance and packaging

Appearance

Bright pink, biconvex, oval film-coated tablet

Package unit

60 tablets/box[(10 tablets/PTP*6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.